| Identification | Back Directory | [Name]
ST7612AA1 | [CAS]
1428535-92-5 | [Synonyms]
ST7612AA1
ST 7612AA1; ST-7612AA1
QGYPCQAYENIOOF-DLBZAZTESA-N | [Molecular Formula]
C20H27N3O4S | [MDL Number]
MFCD28502132 | [MOL File]
1428535-92-5.mol | [Molecular Weight]
405.51 |
| Hazard Information | Back Directory | [Description]
ST7612AA1 is a new and potent HDCA inhibitor with potential anticancer activity. ST7612AA1 showed an in vitro activity in the nanomolar range associated with a remarkable in vivo antitumor activity, highly competitive with the most potent HDAC inhibitors, currently under clinical trials. | [Uses]
ST7612AA1 is a histone deacetylase (HDAC) inhibitor that controls chromatin condensation and DNA transcription by removing acetyl groups from histones. ST7612AA1 is also a potent HIV reactivation inducer, and its reactivation activity is exerted without activating or proliferating CD4+T cells, and can be used in the study of HIV reactivation strategies and elimination of viral reservoirs[1]. | [References]
[1] Badia, et al. The thioacetate-ω (γ-lactam carboxamide) HDAC inhibitor ST7612AA1 as HIV-1 latency reactivation agent. Antiviral research 123 (2015): 62-69. DOI:10.1016/j.antiviral.2015.09.004 |
|
|